Determination of repaglinide in human plasma by high-performance liquid chromatography–tandem mass spectrometry  by Zhang, Jie et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2011;1(1):40–452211-3835 & 2011 In
hosting by Elsevier B
Peer review under re
doi:10.1016/j.apsb.20
$Project supporte
Pillar Program durin
P.R. China.
nCorresponding au
E-mail address: gwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Determination of repaglinide in human plasma
by high-performance liquid chromatography–tandem
mass spectrometry$Jie Zhanga, Feng Gaoa, Xin Guana, Yan-tong Suna,b, Jing-kai Gua,n,
J. Paul FawcettcaResearch Center for Drug Metabolism, College of Life Science, Jilin University, Changchun 130012, People’s Republic of China
bSchool of Pharmaceutical Sciences, Jilin University, Changchun 130012, People’s Republic of China
cSchool of Pharmacy, University of Otago, Dunedin, New Zealand
Received 11 December 2010; revised 3 January 2011; accepted 15 March 2011KEY WORDS
Repaglinide;
Pharmacokinetics;
LC–MS/MS;
Human plasmastitute of Materia M
.V. All rights rese
sponsibility of Inst
11.04.004
d by grants from N
g the Eleventh Fiv
thor. Tel./fax: þ86
ujk@mail.jlu.edu.cAbstract A rapid and sensitive method based on high-performance liquid chromatography–
tandem mass spectrometry (LC–MS/MS) has been developed for the determination of repaglinide
in human plasma. The analyte and internal standard (I.S.), diazepam, were extracted from plasma
(25 mL) by liquid–liquid extraction with diethyl ether–dichloromethane (60:40, v/v) and separated
on a XDB-C18 column using acetonitrile–ammonium acetate buffer (pH 6.8, 0.01 mol/L) as mobile
phase. The retention times of repaglinide and I.S. were 1.95 and 2.35 min, respectively. Detection
was carried out using API 4000 mass spectrometer with an ESI interface operating in the
multiple reaction monitoring (MRM) mode. The assay was linear over the concentration range
0.050–50 ng/mL with a limit of detection (LOD) of 0.010 ng/mL. Intra- and inter-day precisions
(as relative standard deviation, R.S.D.) were r5.07% and r11.2%, respectively, and accuracyedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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Figure 1 Full-scan
Determination of repaglinide in human plasma by high-performance LC–MS/MS 41(as relative error, R.E.) was from 0.593% to 1.26%. The assay was successfully applied
to a pharmacokinetic study involving a single oral administration of a tablet containing 2 mg
repaglinide to each of 10 healthy volunteers.
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An increasing number of people worldwide suffer from type 2
diabetes mellitus (T2DM). Although this chronic disease can
be controlled through diet, exercise and hypoglycaemic drugs,
the control of blood glucose and reversal of insulin resistance
is never adequate to avoid severe long-term complications
such as cardiovascular disease, peripheral vascular disease,
stroke, diabetic neuropathy, amputations, renal failure and
blindness1. Accordingly, research is focusing on new targets
and therapeutic agents to reduce morbidity and mortality andproduct ion mass spectra of [Mthe need for insulin injections. In the development of such
agents, sensitive analytical methods are required for their
quantitation in clinical trials.
Repaglinide (2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-
ylphenyl) butyl] amino]-2-oxo-ethyl] benzoic acid) (Fig. 1), a
meglitinide analog, is an oral hypoglycemic agent used for the
management of T2DM. It is particularly useful when metfor-
min cannot be used due to adverse effects, when metformin
fails to adequately control blood glucose levels or when there
is a need for ﬂexible dosing. It may also have an advantage in
diabetic patients with renal impairment since it is eliminatedþH]þ ions of (A) repaglinide and (B) diazepam.
Jie Zhang et al.42through biliary excretion2. It is characterized by relatively
short duration of action and as monotherapy is usually
administered at a dosage of 0.5–4 mg three times daily. The
major metabolites of repaglinide are a dicarboxylic acid, an
aromatic amine, or acyl glucuronide3. A previous study
reported that the major metabolites of repaglinide have no
hypoglycaemic activity4.
Several methods have been applied to determine the
repaglinide in human biological samples involving competitive
solid-phase enzyme immunoassay5, HPLC with electrochemi-
cal6, ultraviolet7 or diode-array detection8. The LC–MS/MS
method has been developed to determine the repaglinide
concentration in monkey plasma9 and equine plasma and
urine10, but the LLOQ in the method described by Wang and
Miksa9 is 1 ng/mL, which is not sufﬁcient for clinical study.
For the same reason, the method described by Ho et al.10 is
not sensitive enough, either. In addition, the lake of matrix
effect evaluation and stability evaluation that is very impor-
tant in pharmacokinetic study11, may preclude its further
utilization in clinical trials. There is also an LC–MS/MS12
method reported for the quantitation of repaglinide in human
plasma, and the advantage of our method is using a relative
small volume of plasma (25 mL compared to 200 mL) but more
sensitive. In this paper we reported a sensitive LC–MS/MS
method (LLOQ of 0.050 ng/mL) requiring a small volume of
plasma (25 mL), simple sample preparation and short running
time (2.6 min). The method has been successfully applied to a
pharmacokinetic study in healthy volunteers given a single
oral dose of a repaglinide 2 mg tablet.
2. Materials and methods
2.1. Chemicals and reagents
Repaglinide (purity499.0%) was supplied by Beijing Beilu
Pharmaceutical Co., Ltd. (Beijing, China). Diazepam (pur-
ity499.0%) for use as internal standard (I.S.) was purchased
from the National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China). HPLC grade acet-
onitrile and methanol were purchased from Fisher Scientiﬁc
(Fair Lawn, NJ, USA). All other reagents were of analytical
grade and were used without further puriﬁcation. Distilled
water, prepared from demineralized water, was used through-
out the study. Blank (drug free) human plasma was obtained
from the Changchun Blood Donor Service (Changchun,
China).
2.2. LC–MS/MS conditions
Liquid chromatography employed an Agilent 1100 series
HPLC system (Agilent, Palo Alto, CA, USA), including a
binary pump, an autosampler, and a column oven maintained
at 35 1C. Chromatography utilized a Zorbax Eclipse XDB-C18
column (150 mm 4.6 mm i.d., 5 mm) with a mobile phase
consisting of 70% acetonitrile and 30% ammonium acetate
buffer (pH 6.8, 0.01 mol/L) at a ﬂow rate of 1.2 mL/min. An
approximately 1:1 split of the column elute was included
allowing 0.6 mL/min to enter the mass spectrometer.
Mass spectrometric detection utilized an API 4000 mass
spectrometer (Applied Biosystems Sciex, Ontario, Canada)
equipped with an electrospray ionization (ESI) source operatedin the positive ion mode. Detection was carried out at unit
resolution for both Q1 and Q3 with a dwell time of 200 ms per
channel. Multiple reaction monitoring (MRM) transitions
were m/z 453.2-230.3 and m/z 453.2-162.4 for repaglinide
and m/z 285.2-193.1 for diazepam. Optimized MS para-
meters were as follows: Curtain gas, gas 1 and gas 2 (all
nitrogen) 15, 40 and 40 units, respectively; ion spray voltage
4000 V; source temperature 450 1C; declustering potentials
(DP) 55 V for repaglinide and 80 V for I.S.; collision energies
(CE) 37 eV (m/z 453.2-230.3) and 30 eV (m/z 453.2-162.4)
for repaglinide and 42 eV for diazepam.
2.3. Calibration and quality control (QC) samples
Stock solutions of repaglinide (1.0 mg/mL) and I.S. (1.0 mg/mL)
were prepared in methanol. A series of standard solutions of
repaglinide were prepared by diluting the stock solution with
methanol–water (50:50, v/v) to give concentrations of 0.050, 0.15,
0.50, 1.5, 5.0, 15 and 50 ng/mL. Calibration samples were
prepared by spiking 25 mL blank plasma samples with 25 mL
aliquots of standard solutions. Low, medium and high concen-
tration QC samples (0.15, 1.5, 15 ng/mL) were prepared inde-
pendently in the same way. An I.S. working solution with
concentration 150 ng/mL was also prepared in methanol–water
(50:50, v/v). Samples were stored at 4 1C when not in use.
2.4. Sample preparation
Frozen human plasma samples stored at 80 1C were thawed
at room temperature and vortexed for 30 s. To 25 mL human
plasma in a glass tube, 25 mL I.S. working solution, 25 mL
methanol–water (50:50, v/v) (or a calibration sample or QC
sample) and 3 mL diethyl ether–dichloromethane (60:40, v/v)
were added. The mixture was vortex-mixed for 30 s and
centrifuged at 1500 g for 5 min after which the supernatant
was transferred to a clean glass tube and evaporated to
dryness at 40 1C under a gentle stream of nitrogen. The
residue was reconstituted in 100 mL mobile phase of which
20 mL was injected into the LC–MS/MS system.
2.5. Assay validation
Assay validation was performed according to FDA guide-
lines11. Linearity was assessed by weighted (1/x2) least-squares
linear regression of analyte–I.S. peak area ratios based on
three independent calibration curves prepared on three sepa-
rate days. Precision (as relative standard deviation, R.S.D.)
and accuracy (as relative error, R.E.) were evaluated by assay
of six replicate QC samples on three different days. The lower
limit of quantitation (LLOQ) was deﬁned as the lowest
concentration of analyte that could be determined with
precision of r20% and accuracy within 720%. The limit of
detection (LOD) was taken as the concentration with signal-
to-noise ratio of 3. Selectivity of the method was carried out
by comparing the chromatograms of six different batches of
blank human plasma with corresponding spiked plasma
samples. Recoveries of analyte and I.S. were determined by
comparing the peak areas in extracted QC samples with those
in post-extraction blank samples spiked at the corresponding
concentrations. Matrix effects for repaglinide were evaluated
by comparing peak areas in extracted samples of blank plasma
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from pure standard solutions at the same concentrations.
Matrix effects for the I.S. were assessed at the concentration
used in the assay in the same way. A stability study involved
assay of QC samples after storage at –80 1C for one month, at
room temperature for 6 h and after three freeze–thaw cycles.
Post-processing stability of reconstituted solutions in the
autosampler at room temperature for 8 h was also assessed.2.6. Pharmacokinetic study
The method was applied to a pharmacokinetic study involving
10 healthy volunteers given a single oral dose of a repaglinide
2 mg tablet. The clinical protocol was approved by the Ethics
Committee of Peking University First Hospital, China. All
volunteers gave written informed consent before entering the
study. During the study, no subject was allowed to take
alcohol or any other medication. Blood samples were collected
into heparinized glass tubes before and at 0.25, 0.5, 0.75, 1,Figure 2 Typical MRM chromatograms of (I) repaglinide and (II) d
spiked with 0.050 ng/mL repaglinide and 150 ng/mL I.S. and (C) a pla
of a repaglinide 2 mg tablet.1.5, 2, 2.5, 3, 4, 5 and 6 h after dosing. Plasma was separated
immediately by centrifugation at 3000 g for 10 min and
stored at 80 1C until analysis. Pharmacokinetic parameters
were calculated using Topﬁt 2.0.3. Results and discussion
3.1. Method development
In optimizing MS conditions, it was found that repaglinide
ionized in both positive and negative modes but gave much
higher ionization efﬁciency in the positive ion mode. Full-scan
product ion mass spectra of repaglinide and I.S. are shown in
Fig. 1. The MRM transition of repaglinide at m/z 453.2-
230.3 was more intense than that at m/z 453.2-162.4 leading
to the former being used as quantiﬁer and the latter as
qualiﬁer.
In developing the chromatographic conditions, a number of
reversed phase HPLC columns (Hypersil ODS2, Zorbax extendiazepam in human plasma: (A) blank plasma; (B) blank plasma
sma sample from a human volunteer 4 h after oral administration
Table 2 Stability data for repaglinide under various
conditions (n¼3).
Storage conditions Concentration (ng/mL)
Nominal Found
(mean7SD)
Room temperature for
6 h (in human plasma)
0.150 0.15370.00755
1.50 1.4770.0666
15.0 15.170.569
Freezing for 30 days at
80 1C (in human plasma)
0.150 0.15270.00721
1.50 1.5470.0757
15.0 13.970.208
Three freeze/thaw cycles
(in human plasma)
0.150 0.14570.0144
1.50 1.5870.0100
15.0 14.570.289
Post-extraction stability at
room temperature for 8 h
0.150 0.14170.00586
1.50 1.5870.0351
15.0 15.670.458
Figure 3 Mean plasma concentration–time curve for repaglinide
after oral administration of a repaglinide 2 mg tablet (data are
mean7SD, n¼10).
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phase combinations of acetonitrile, methanol, water and
ammonium acetate with or without formic acid were also
evaluated. The Zorbax Eclipse XDB-C18 gave the best combi-
nation of sensitivity and peak shapes; acetonitrile produced a
shorter retention time than methanol; ammonium acetate
produced better peak shapes than water; addition of formic
acid decreased sensitivity and extended the retention times. On
this basis a mixture of 70% acetonitrile and 30% ammonium
acetate buffer (pH 6.8, 0.01 mol/L) was adopted as the
mobile phase.
In choosing the I.S., a number of compounds (diazepam,
tramadol, metformin, acetaminophen, diphenhydramine,
huperzine A, codeine and telmisartan) were evaluated. Diaze-
pam was chosen because, although both it and diphenhydra-
mine showed similar chromatographic behavior to repaglinide,
diphenhydramine was susceptible to tailing. Using a ﬂow rate
of 1.2 mL/min, the retention times of repaglinide and I.S. were
1.95 and 2.35 min, respectively.
3.2. Sample preparation
Liquid–liquid extraction was chosen for sample preparation
based on its reliability and cost effectiveness relative to solid
phase extraction. A number of organic solvents (diethyl ether,
dichloromethane, hexane, isopropanol and ethyl acetate)
alone and in different combinations were evaluated. Diethyl
ether–dichloromethane (60:40, v/v) was found to give high
recovery of both analyte and I.S. with minimal matrix effects.
3.3. Assay validation
Fig. 2 showed representative chromatograms of blank plasma,
plasma spiked with repaglinide at the LLOQ (0.050 ng/mL)
and a plasma sample from a healthy volunteer after admin-
istration of repaglinide. The assay was free of interference
from endogenous substances in plasma.
Calibration curves showed good linearity in the concentration
range 0.050–50 ng/mL with an LLOQ of 0.050 ng/mL and LOD
of 0.010 ng/mL. The accuracy and precisions of LLOQ were listed
in Table 1. A typical regression equation for the calibration curve
was y¼4.89 102xþ2.12 104, r¼0.9982. Intra- and inter-day
precisions were below 5.07% and 11.2%, respectively. The
accuracy ranged from 0.593% to 1.26% (Table 1).
The recoveries of repaglinide at 0.15, 1.5 and 15 ng/mL
were 98.2%73.4%, 99.1%71.4% and 94.0%75.2%, respec-
tively. The recovery of the I.S. was 95.1%75.1%. MatrixTable 1 Accuracy and precision for the analysis (data are base
repaglinide in human plasma.
Concentration (ng/mL) Precision (RS
Nominal Found (mean7SD) Intra-day
0.150 0.14870.00836 5.07
1.50 1.4870.0795 3.98
15.0 14.970.800 4.72
0.0500 0.051270.00263effects of repaglinide at low, medium and high QC concentra-
tions were 101.6%71.3%, 92.7%76.1% and 90.2%71.7%,
respectively. A matrix effects study of the I.S. gave a result of
95.5%73.7%. Table 2 presented the stability data. Repagli-
nide proved to be stable under all the conditions tested.d on assay of 6 replicates on 3 different days) and LLOQ of
D/%) Accuracy (RE/%)
Inter-day
8.78 1.15
11.2 1.26
8.80 0.593
5.15 2.15
Table 3 Pharmacokinetic parameters for ten healthy volunteers after oral administration of a repaglinide 2 mg tablet.
Volunteer
number
Cmax (ng/mL) tmax (h) t1/2 (h) AUC0–6 h
(ng  h/mL)
CL (mL/min) MRT (h)
1 8.87 0.50 0.90 21.77 1500 1.97
2 18.10 0.50 1.22 55.47 562 2.54
3 16.10 1.50 1.16 37.96 842 2.05
4 11.00 0.50 1.17 28.02 1150 1.94
5 23.70 0.50 1.08 44.31 735 1.59
6 17.40 1.00 1.20 37.87 843 2.08
7 15.30 0.75 1.22 40.47 776 2.17
8 16.20 0.50 0.87 33.38 983 1.87
9 13.90 0.75 0.95 23.64 1390 1.51
10 12.20 0.75 1.12 24.77 1300 1.92
Mean 15.28 0.73 1.09 34.77 1008 1.96
7SD 4.16 0.32 0.13 10.60 312 0.29
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The mean plasma concentration–time proﬁle was shown in
Fig. 3 and corresponding pharmacokinetic parameters
were listed in Table 3. The time to reach maximum plasma
concentration (tmax) and the elimination half-life (t1/2) were
similar to the values previously reported for repaglinide given
as a single oral 2 mg dose5. The maximum plasma concentra-
tions (Cmax) and areas under the plasma concentration–time
curve (AUC0t) were in the range 8.87–23.7 ng/mL and 21.8–
55.5 ng h/mL, respectively, indicating high inter-individual
variability. This phenomenon has been attributed to the fact
that repaglinide is a substrate of the organic anion transport-
ing polypeptide (OATP) and of CYP2C8 both of which
exhibit genetic polymorphism13,14. The results conﬁrm that
the assay is suitable for clinical pharmacokinetic studies of
repaglinide.
4. Conclusions
A rapid and sensitive LC–MS/MS method for the determination
of repaglinide in human plasma has been developed and validated.
The method has high sensitivity (LLOQ of 0.050 ng/mL) and
requires only a small volume of human plasma (25 mL). The
method also exhibited excellent performance in terms of recovery
and matrix effect. Simple sample preparation and short run time
allow high sample throughput for clinical studies.
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